ClinicalTrials.gg
Not yet recruitingNCT07698821Updated Jul 13, 2026

Emotion Regulation Program for Substance Use Disorders

An interventional study of Emotion Regulation Program in Substance Use Disorder (SUD), sponsored by The Catholic University of Korea. Not yet recruiting at 2 sites in South Korea. Open to participants aged 19 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-07-13.

Sponsored by The Catholic University of Korea · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
19 Years to 65 Years
Sex
All
01

Study summary

This study examines whether a newly developed eight-session psychosocial treatment program, called the Emotion Regulation Program, can be delivered in real-world hospital settings to people receiving inpatient care for substance use disorders in Korea, and whether it shows early signs of benefit. The program combines motivational interviewing, acceptance and commitment therapy, and group activities, and is delivered twice a week over about four weeks (eight 50-minute sessions). About 20 adults will take part at two psychiatric hospitals.

Participants complete brief questionnaires and a short interview about their craving, motivation to change, difficulties in emotion regulation, self-compassion, depression, and drug use history before the program, immediately before and after each session, within one week after the program ends, and again at 1 month and 3 months after completion. After the program, some participants also join a small group discussion (focus group interview) to share their experience of the program.

Because this is a small, single-group preliminary (pilot) study without a comparison group, its primary purpose is to assess feasibility, that is, whether the program and the assessment approach work well enough, and to obtain preliminary effect and variability estimates to inform the design of a future large-scale randomized controlled trial.

Read the detailed description

Background: Substance use among the Korean population has increased rapidly, with spread into adolescents and people in their twenties. Yet standardized, evidence-based psychosocial treatment programs and a corresponding clinician training and certification system are not well established in Korea. Evidence-based psychosocial interventions such as cognitive behavioral therapy, motivational interviewing, community reinforcement approaches, and 12-step facilitation are widely used as standard care in other countries, but comparable, locally validated programs are scarce in Korea. To address this gap, a Korean psychosocial treatment program (the Emotion Regulation Program) was developed, and this preliminary study evaluates its feasibility and preliminary effectiveness.

Objectives:

  1. Primary objective: to evaluate the real-world feasibility of delivering the Emotion Regulation Program to inpatients with substance use disorders.
  2. Secondary objective: to examine preliminary changes in craving (VAS-C), motivation to change (URICA-DO), difficulties in emotion regulation (DERS-SF), self-compassion (K-SCS), depression (PHQ-9), and drug use history and treatment service utilization, and to assess whether these measures are suitable for a future comparative trial.
  3. Tertiary objective: to explore participants' subjective experience and the acceptability of the program through a focus group interview, in order to refine the treatment manual and operational protocol for a future randomized controlled trial.

Design and setting: This is a single-arm, pre-post study with follow-up, without a control group. A total of 20 participants (10 per site) will be enrolled at two psychiatric hospitals that provide care to a large proportion of patients with drug use disorders in Korea (Incheon Chamsarang Hospital and Daegu Daedong Hospital). Study planning, rater training, informed consent storage, data management, and statistical analysis are coordinated centrally by the Catholic University of Korea. The two participating sites do not have their own IRB and are reviewed under the Uijeongbu St. Mary's Hospital IRB.

Intervention: The program consists of eight 50-minute group sessions delivered twice weekly over approximately four weeks. It integrates motivational interviewing, acceptance and commitment therapy, and group therapy, and draws on emotion-regulation and self-compassion skills. Session themes are: (1) understanding emotions and following the body's signals; (2) emotion regulation strategies I: grounding oneself through the senses when shaken; (3) emotion regulation strategies II: practicing choice rather than being swept away by emotion; (4) building a personal emotion-response scenario for moments of crisis; (5) facing the self-critical voice; (6) protecting oneself with warmth in difficult moments; (7) noticing and savoring positive moments; and (8) organizing a personal emotion-regulation routine to sustain going forward.

Assessment schedule: Baseline assessment occurs within one week before the program. Craving is assessed immediately before and after each session, along with session satisfaction and a therapist treatment-fidelity self-assessment. Post-intervention assessment occurs within one week after the program, followed by a focus group interview. Follow-up assessments are conducted at 1 month and 3 months after program completion.

Statistical analysis: Feasibility will be summarized using recruitment, retention, session attendance, and assessment completion rates. Change in continuous outcomes over time (pre, post, follow-up) will be analyzed using repeated-measures analysis of variance and linear mixed models; where covariate adjustment for repeated measures is needed, generalized estimating equations will be used. Analyses adjust for sociodemographic covariates and indication variables, or use stratified comparison. Missing data judged to be MCAR/MAR will be handled via maximum likelihood estimation within linear mixed models or multiple imputation, with sensitivity analyses. The main analysis is based on the full analysis set, with the per-protocol set as a supportive analysis. Qualitative focus group data will be transcribed and analyzed using thematic analysis (Braun \& Clarke, 2006) by at least two independent coders.

02

Conditions studied

  • Substance Use Disorder (SUD)

Keywords

  • Psychosocial intervention
  • Craving
  • Group therapy
  • Acceptance and Commitment Therapy
  • Emotion regulation
  • Self-compassion
  • Motivation to change
03

In context

Substance-Related Disorders

2,238 studies on the registry are indexed under Substance-Related Disorders; 409 are open to participants now.

This study's planned enrollment of 20 is below the median of 108 across 1,840 interventional studies indexed under Substance-Related Disorders.

Browse Substance-Related Disorders studies →

Lead sponsor

The Catholic University of Korea is the lead sponsor of 155 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 19 to 65 years who can understand the study purpose and procedures and provide written
  • Currently hospitalized (inpatient)
  • Able to communicate and complete questionnaires in Korean
  • Physically able to participate in program activities
  • Has completed detoxification treatment
  • Meets indication thresholds: DAST-10 score >= 2 and >= 2 criteria

Exclusion criteria

Exclusion Criteria:

  • Cognitive impairment that precludes communication
  • Physical conditions that preclude program participation (e.g., musculoskeletal disorder, severe cardiopulmonary disease)
  • Acute psychotic symptoms or risk of self-harm or harm to others
  • At risk of disrupting group activities such that focus group participation is not feasible
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Emotion Regulation Program

    All participants receive the Emotion Regulation Program, an eight-session group-based psychosocial treatment delivered twice weekly (50 minutes per session) over approximately four weeks. The program integrates motivational interviewing, acceptance and commitment therapy, and group therapy, and draws on emotion-regulation and self-compassion skills, covering emotional awareness, sensory grounding, choosing responses over reactions, crisis coping, self-compassion, savoring positive emotions, and a personalized emotion-regulation routine.

    Behavioral: Emotion Regulation Program

Interventions

  • BehavioralEmotion Regulation Program

    Eight 50-minute group sessions delivered twice weekly over approximately four weeks. Session 1: understanding emotions and following the body's signals. Session 2: emotion regulation strategies I (grounding oneself through the senses when shaken). Session 3: emotion regulation strategies II (practicing choice rather than being swept away by emotion). Session 4: building a personal emotion-response scenario for moments of crisis. Session 5: facing the self-critical voice. Session 6: protecting oneself with warmth in difficult moments. Session 7: noticing and savoring positive moments. Session 8: organizing a personal emotion-regulation routine to sustain going forward. Core techniques are motivational interviewing, acceptance and commitment therapy, and group therapy, incorporating emotion-regulation and self-compassion skills.

06

What researchers measure

Primary outcomes

  1. Feasibility: Program Completion (Retention) Rate

    Proportion of enrolled participants who complete all eight sessions of the Emotion Regulation Program. Feasibility is further characterized by recruitment rate, session attendance, and assessment completion rates.

    Time frame: From enrollment through the end of the 8-session intervention (approximately 4 weeks)

  2. Change in Craving (VAS-C)

    Craving measured by the Visual Analog Scale for Craving (VAS-C), ranging from 0 to 100 mm (0 = no craving, 100 = constant craving); higher scores indicate greater craving (worse outcome). Change from baseline is assessed at post-intervention and follow-up.

    Time frame: Immediately before and immediately after each of the 8 sessions (over approximately 4 weeks); baseline (within 1 week before the program); within 1 week post-intervention; 1 month and 3 months after completion

Secondary outcomes

  1. Change in Motivation to Change (URICA-DO)

    Motivation to change (readiness) measured by the Korean version of the University of Rhode Island Change Assessment for Drug Offenders (URICA-DO), a 24-item scale rated from 1 (strongly disagree) to 5 (strongly agree) with four subscales (Precontemplation, Contemplation, Action, Maintenance). A Readiness to Change score is computed as the sum of the mean Contemplation, Action, and Maintenance subscale scores minus the mean Precontemplation subscale score (range -2 to 14); higher scores indicate greater readiness to change (better outcome).

    Time frame: Baseline (within 1 week before program), post-intervention (within 1 week after program), 1 month and 3 months after completion

  2. Change in Difficulties in Emotion Regulation (DERS-SF)

    Difficulties in emotion regulation measured by the Difficulties in Emotion Regulation Scale-Short Form (DERS-SF), an 18-item scale rated from 1 to 5 (total range 18 to 90); higher scores indicate greater difficulties in emotion regulation (worse outcome).

    Time frame: Baseline, post-intervention (within 1 week), 1 month and 3 months after completion

  3. Change in Self-Compassion (K-SCS)

    Self-compassion measured by the Korean version of the Self-Compassion Scale (K-SCS), a 26-item scale rated from 1 to 5; higher mean scores indicate greater self-compassion (better outcome).

    Time frame: Baseline, post-intervention (within 1 week), 1 month and 3 months after completion

  4. Change in Depression (PHQ-9)

    Depressive symptoms measured by the Patient Health Questionnaire-9 (PHQ-9), a 9-item scale rated from 0 to 3 (total range 0 to 27); higher scores indicate more severe depression (worse outcome).

    Time frame: Baseline, post-intervention (within 1 week), 1 month and 3 months after completion

  5. Change in Drug Use and Treatment Service Utilization

    Self-reported drug use history and treatment service utilization assessed via a structured 1:1 interview. Recall window is the past 30 days at most time points and the past 2 months at the 3-month follow-up.

    Time frame: Baseline, post-intervention (within 1 week), 1 month and 3 months after completion

  6. Program Acceptability (Focus Group Interview)

    Acceptability and subjective experience of the program explored through a focus group interview using a semi-structured guide, analyzed by thematic analysis (Braun \& Clarke, 2006).

    Time frame: Within 1 week after program completion

Other outcomes

  1. Session Usefulness and Therapeutic Alliance

    Participant-rated helpfulness of each session and therapeutic alliance on a visual analog scale from 0 to 10 (0 = not helpful at all, 10 = very helpful); higher scores indicate greater perceived usefulness and alliance (better outcome).

    Time frame: Immediately after each of the 8 sessions (over approximately 4 weeks)

  2. Treatment Fidelity (Adherence Rate)

    Therapist self-assessed treatment fidelity comprising common structural-fidelity items, session-specific core-practice items, and overall clinical-process fidelity items (yes/no), summarized as an adherence rate per session and per therapist.

    Time frame: Immediately after each of the 8 sessions

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: No — This is a small, single-group pilot study involving sensitive data from patients with substance use disorders. Given the limited sample size and re-identification risk, individual participant data will not be shared. Only de-identified, aggregated results will be reported.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07698821
Responsible party
Hae Kook Lee (Professor, The Catholic University of Korea) — Principal investigator
First posted
Jul 13, 2026
Start date
Sep 2026 (estimated)
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jul 13, 2026

Study contacts

Hae Kook Lee, MD, PhD
Contact
policyhklee@gmail.com
+82-31-820-3050
Hae-Ryoung Chun, PhD
Contact
mamimihae@catholic.ac.kr
+82-10-6567-7833
Hae Kook Lee
principal investigator · The Catholic University of Korea

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion